Ipsen

Ipsen is a French pharmaceutical company headquartered in Paris, France.[1]

Ipsen S.A.
TypePublic
Euronext: IPN
CAC Mid 60 Component
ISINFR0010259150 
IndustryPharmaceutical
Founded1929
HeadquartersParis, France
Key people
Marc de Garidel (Non-executive Chairman)
David Loew (Chief Executive Officer)
Products 
Number of employees
5,700
Websitewww.ipsen.com

It develops and markets medications used in oncology, neuroscience and rare diseases along with consumer healthcare products.[1]

It is publicly traded on the Euronext Paris as part of the SBF 120 index.[1]

Ipsen, founded by Henri Beaufour in 1929, has more than 5,700 employees worldwide, marketing over 20 drugs in 115 countries.

Overview

Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €2.56 billion in 2019.

The Beaufour family, which ranks as the 42nd richest family in France, still owns 57% of its shares and 73% of its voting rights,[2]:217 and two of its members, Anne Beaufour and Henri Beaufour, sit on its board of directors.[3][4][5]

In 2019, Ipsen spent close to €388.8 million—15.1% of consolidated sales—on research and development.

In February 2015, the company announced it would Canbex Therapeutics $6.8 million upfront upon completion of a Phase IIA study of Canbex's lead multiple sclerosis compound, VSN16R.[6]

in October 2016, European Commission approves Ipsen's Cabometyx (Cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.[7]

The CABOSUN study, presented at the European Society for Medical Oncology (ESMO) 2016 congress, showed Cabometyx (Cabozantinib) can decrease the rate of disease progression or death by 31% in advanced renal cell carcinoma (RCC).[8]

In November 2018, the European Commission (EC) approved Cabometyx (cabozantinib) 20, 40, 60 mg as a monotherapy for hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib. This approval allows for the marketing of Cabometyx (cabozantinib) in this indication in all 28 member states of the European Union, Norway and Iceland.

In February 2019, Ipsen announced it would acquire Clementia Pharmaceuticals, a biopharmaceutical company specialized in rare bone diseases, for $1.3 billion.[9] This acquisition is the largest in the history of Ipsen. In April 2019, Ipsen announced the deal was finalized.[10]

Research and development

In 2019, Ipsen's R&D expenditure totaled close to €388.8 million, representing more than 15.1% of group sales.

Ipsen's main research and development centers are located in Cambridge (Massachusetts, United States), Milton Park / Oxford (United Kingdom) and Paris Saclay (France).

Governance

Board of directors

The board of directors sets the strategic guidelines for Ipsen's activities and oversees implementation.

Management team

Corporate executives are responsible for managing the group's operations and coordinating the group's various scientific, legal, financial, commercial and strategic actions.

  • David Loew, CEO
  • Aymeric Le Chatelier, CFO
  • Bartek Bednarz, executive vice president, head of global product and portfolio strategy
  • Dominique Bery, executive vice president, strategy & transformation
  • François Garnier, executive vice president, general counsel
  • Benoît Hennion, executive vice president, consumer healthcare
  • Steven Hildemann, MD, executive vice president, chief medical officer, head of
  • Dominique Laymand, executive vice president, ethics and social responsibility officer
  • Philippe Lopes-Fernandes, executive vice president, chief business officer
  • Howard Mayer, MD, executive vice president, head of research and development global medical affairs and pharmacovigilance
  • Régis Mulot, executive vice president, chief human resources officer
  • Aidan Murphy, executive vice president, technical operations
  • Richard Paulson, executive vice president, chief executive officer of Ipsen North America
  • Patrice Zagame, executive vice president, specialty care international

Ipsen Foundation

In 1983, Ipsen founded the Ipsen Foundation (Fondation Ipsen) with the help of the Fondation de France to track progress in biomedical research.[11][12] It is headquartered in Boulogne-Billancourt.[11][12] It has organised 64 colloquia, and it has partnered with the World Health Organization, the Fondation Nationale de Gérontologie, Harvard University, the Salk Institute for Biological Studies, the Massachusetts General Hospital, and the academic journals Nature and Cell.[11]

References
  1. "Profile & key figures". Ipsen. Archived from the original on 1 February 2013.
  2. 2015 Registration Document (PDF) (Report). 29 March 2016. Archived from the original (PDF) on 4 June 2016.
  3. Challenges wealth ranking. Challenges.fr.
  4. Challenges. Challenges.fr. (internet archive > https://web.archive.org/web/20160602202417/http://www.challenges.fr/classements/fortune/fiche/famille-beaufour;44.html )
  5. Board of Directors Archived 1 February 2013 at the Wayback Machine. Ipsen.com.
  6. "Ipsen Gains Option to Buy Canbex Therapeutics for $6.8M+". 24 February 2015.
  7. European Commission approves Ipsen’s Cabometyx for treatment of advanced renal cell carcinoma
  8. Ipsen eyes first-line licence for new advanced kidney cancer drug Cabometyx
  9. "Ipsen to buy Clementia Pharmaceuticals in deal worth up to $1.3..." 25 February 2019 – via uk.reuters.com.
  10. "Ipsen completes acquisition of Clementia Pharmaceuticals". 18 April 2019 – via Pharmacy Business.
  11. Fondation Ipsen Archived 1 February 2013 at the Wayback Machine. Ipsen.com.
  12. (in French) Fondation de France Archived 16 April 2014 at the Wayback Machine. Fondation de France.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.